• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

byConstance Wu
August 27, 2019
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Patients with migraine treated with rimegepant during an acute event had resolution of pain and their most bothersome symptoms 2 hours after onset more frequently than patients treated with placebo.

2. Incidence of adverse events were similar for patients treated with either rimegepant or placebo.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Migraine is a common and debilitating headache condition. Treatment with triptans for acute episodes are often either not effective or can be contraindicated in certain patients. Calcitonin gene–related peptide (CGRP) has been associated with migraine pathology, and prior studies have shown inhibition of CGRP can effectively treat migraine. This phase 3 randomized controlled trial compared the CGRP small molecule inhibitor rimegepant to placebo for acute migraine treatment. The primary outcome of pain 2 hours after treatment administration showed more patients were pain free and free of their most bothersome symptoms when treated with rimegepant compared to placebo. Nausea and urinary tract infections were the most common adverse events and reported at similar rates in the treatment and placebo groups.

This large randomized study provides clinically meaningful, patient-centric data to suggest rimegepant as an efficacious treatment of acute migraine. The study is significantly limited by its lack of comparison to a triptan, or other active drug treatment.

Click to read the study in NEJM

RELATED REPORTS

Bedside parameters may help predict chronic post-traumatic head and neck pain

Triptans may be the most effective treatments available for acute episodic migraine

Patient values and preferences when considering migraine prevention options

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: headachemigrainerimegepanttriptan
Previous Post

2 Minute Medicine Rewind August 26, 2019

Next Post

FDG-PET scanning demonstrates prognostic significance in prosthetic valve infective endocarditis

RelatedReports

Chronic Disease

Bedside parameters may help predict chronic post-traumatic head and neck pain

May 25, 2025
Patients report persistent quality-of-life impairments following ruptured brain aneurysms
Neurology

Triptans may be the most effective treatments available for acute episodic migraine

March 24, 2025
Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial
Neurology

Patient values and preferences when considering migraine prevention options

February 3, 2025
Galcanezumab reduces the frequency of episodic cluster headaches
Chronic Disease

Timely diagnosis of migraine may prevent future emergency department

December 3, 2024
Next Post
FDG-PET scanning demonstrates prognostic significance in prosthetic valve infective endocarditis

FDG-PET scanning demonstrates prognostic significance in prosthetic valve infective endocarditis

Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening

Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening

#VisualAbstract: Trial of Galcanezumab in Prevention of Episodic Cluster Headache

#VisualAbstract: Trial of Galcanezumab in Prevention of Episodic Cluster Headache

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.